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Abstract
Mucormycosis (zygomycosis) is an uncommon infection that afﬂicts severely immunocompromised patients and those with poorly con-
trolled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the intro-
duction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association
reﬂects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of
transplant practices and immunosuppression strategies.
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Introduction
Mucormycosis is a unifying term for a group of ﬁlamentous
fungi in the phyla Mucorales that are capable of causing
severe, frequently life-threatening infections in humans.
Agents of mucormycosis (e.g. Rhizopus, Mucor, Cunningha-
mella, Apophysomyces, Absidia, Saksenaea, Rhizomucor) are
found worldwide in soil, decaying organic matter and food
[1]. These fungi are opportunistic pathogens, causing disease
in immunocompromised patients and diabetes patients. A
hallmark of invasive mucormycosis is its rapid progression to
tissue necrosis because of blood vessel invasion and infarc-
tion [2]. The clinical manifestations of mucormycosis include
pulmonary, rhinocerebral, gastrointestinal, cutaneous and dis-
seminated infections, although other uncommon presenta-
tions can be encountered.
Epidemiology and Risk Factors
Among ﬁlamentous fungi, Mucorales have the ability to infect
a broader, more heterogeneous population of human hosts
than other opportunistic moulds. Historically, diabetes mell-
itus has been the most common underlying risk factor. How-
ever, during the past 30 years there has been an increase in
the numbers of mucormycosis patients with malignancy and
those undergoing haematopoietic stem cell transplantation
(HSCT) or solid organ transplantation (SOT) [3]. Addition-
ally, iron overload, ketoacidosis, prolonged high-dose
systemic corticosteroid therapy and penetrating trauma or
burns are well-documented underlying risk factors for
mucormycosis.
Although the number of published reports of mucormycosis
cases has steadily increased since the 1940s [4], the incidence
of this infection has accelerated in many centres in the last
decade. At the University of Texas M. D. Anderson Cancer
Center, for example, the incidence of mucormycosis increased
from 0.0079/1000 patient-days in 1999 (prior to usage of
voriconazole (VRC)) to 0.095/1000 patient-days during
2002–2004 [5,6]. This trend was especially notable in the
HSCT population, in which the proportion of all invasive fungal
infections (IFIs) represented by this mycosis increased from
0.25% during 1989–1998 to 1.55% during 2002–2004 [5].
The recent increase in mucormycosis cases has been tem-
porally linked in many transplant centres to the introduction
and widespread use of VRC, a drug that lacks activity against
the Mucorales [7–9]. Not surprisingly, the increase in cases
of mucormycosis is often associated with a decrease in the
incidence of documented cases of invasive aspergillosis (IA)
[7]. These parallel temporal trends raise the question of
whether mucormycosis has increased because of the
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improved management of more common opportunistic
moulds such as Aspergillus, or whether VRC exerts selective
pressure on the microbiology and pathogenesis of fungal
pneumonia in the immunocompromised host.
Voriconazole Pre-exposure as a Risk Factor
for Mucormycosis
Marty et al. [10] ﬁrst described an increased frequency of
mucormycosis after VRC prophylaxis among recipients of
allogeneic HSCT. Subsequently, several retrospective case
series from geographically distinct transplant centres in the
USA suggested an association between prior VRC exposure
(as prophylaxis or pre-emptive antifungal therapy) and the
subsequent development of mucormycosis (Table 1) [5,11–
15]. Of the 150 cases of mucormycosis from these combined
series, 73 (49%) were encountered in the setting of VRC
prophylaxis.
Zygomycetes species distribution (51% Rhizopus), organ
involvement (half of the cases were pulmonary infections)
and mortality were consistent with earlier reports of muco-
rmycosis prior to the availability of VRC. Although data are
scant, mucormycosis should be an important consideration
in a patient with presumed fungal infection and adequate
VRC serum levels. In a small study, mucormycosis repre-
sented 40% of VRC breakthrough infections, typically associ-
ated with prolonged exposure and VRC steady state levels
>2 mg/L [15].
The association of VRC with breakthrough mucormycosis
has been examined in two prospective studies. A prospective
survey of invasive fungal infections, a controlled study of 393
transplant recipients (Transplant Associated Infection Surveil-
lance Network (TRANSNET)), demonstrated that VRC was
associated more frequently with breakthrough infections
caused by Zygomycetes and Fusarium spp. than with break-
through infections caused by Aspergillus spp. (odds ratio 24.0)
[16]. In the only prospective (single-institution) study of
mucormycosis risk in the context of the relative frequency
of other moulds, Kontoyiannis et al. [5] found that prior
VRC prophylaxis was an independent risk factor for develop-
ing mucormycosis rather than IA in patients with haemato-
logical malignancies.
In contrast with these studies, in a large prospective study
comparing ﬂuconazole and VRC for the prevention of IFIs,
Wingard et al. did not ﬁnd excess numbers of cases of muco-
rmycosis in the VRC-treated group (two mucormycosis
cases in 305 VRC-treated patients and three in 295 ﬂucon-
azole-treated patients) [17]. However, the rate of IFI in both
arms of the study was low (10.6% for the ﬂuconazole group
and 6.6% for the VRC group at 6 months), perhaps indicating
that a relatively lower-risk cohort of HSCT recipients had
been enrolled in the clinical trial.
Is there a Causal Link between VRC
Exposure and Excess Numbers of Cases of
Mucormycosis, or does VRC Make a
Pre-existing Trend More Apparent?
Given that the incidence of mucormycosis was increasing
prior to the widespread use of VRC [6,18,19], the use of this
and other newer antifungal agents may have only accelerated
the progress of a pre-existing trend and the increasing
incidence may, perhaps, represent a marker of changes in
immunosuppression status.
The availability of VRC in oral and parenteral formulations
permits extended periods of antifungal exposure in highly im-
munosuppressed patients. One could hypothesize that HSCT
patients, by not developing aspergillosis during the post-trans-
plant period, might subsequently develop mucormycosis in
the setting of continuous immunosuppression associated with
graft vs. host disease (GvHD) and exposure to high-dose
corticosteroids. Single-centre studies of IFI epidemiology may
support this hypothesis, where mucormycosis was found to
predominate as a ‘very late’ (>100 days after HSCT) infection,
primarily in patients who had received non-myeloablative
conditioning, had received frequent blood transfusions with
evidence of iron overload (ferritin >2000 ng/mL), had chronic
GvHD, and had received high-dose (2–3 mg/kg/day) cortico-
steroids [20]. It is possible that metabolic factors associated
with recurrent transfusions and prolonged high-dose cortico-
steroid therapy (i.e. iron overload, hyperglycaemia), in addi-
tion to GvHD and suppressed cell-mediated immunity, may
favour the development of mucormycosis independent of
VRC exposure, in these chronically immunosuppressed
patients.
Other non-mutually exclusive explanations may exist.
Lamaris et al. [21]) showed that ex vivo exposure of Rhizopus
TABLE 1. Studies of mucormycosis in which voriconazole
(VRC) prophylaxis was included as a possible risk factor
Authors/year/reference
Cases of
mucormycosis, n Study type
Cases on VRC
prophylaxis, %
Marty et al. 2004 [10] 4 Retrospective 75
Siwek et al. 2004 [11] 4 Retrospective 100
Kontoyiannis et al. 2005 [5] 27 Prospective 50
Bethge et al. 2005 [13] 6 Retrospective 50
Schalk et al. 2006 [14] 4 Retrospective 75
TRANSNET 2006 [16] 105 Prospective 45
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oryzae to VRC increases the virulence of the fungus in a cor-
ticosteroid-immunosuppressed mouse model of invasive pul-
monary zygomycosis. This switch to a hypervirulent
phenotype was speciﬁc to VRC pre-exposure because no
increase in mortality was observed with other azoles. How-
ever, the virulence reverted to baseline when exposure to
VRC was terminated, suggesting an unstable epigenetic modi-
ﬁcation rather than a genetic change. Examples of possible
epigenetic modiﬁcations following VRC exposure may include
upregulation of an efﬂux pump involved in the secretion of
virulence factors (i.e. proteases or iron-scavenging sidero-
phores). Alternatively, changes in sterol composition may
result in increased adherence to endothelial surfaces or to
the extracellular matrix (Fig. 1). By contrast with R. oryzae,
pre-exposure of Aspergillus fumigatus to VRC did not enhance
the virulence of the fungus in a non-vertebrate model of
infection [22], suggesting the uniqueness of this phenomenon
for fungi of the phyla Mucoracae.
Challenges in Diagnosis of VRC-associated
Mucormycosis
As mucormycosis typically occurs in patients treated with
VRC for presumed aspergillosis, making an early distinction
between these mycoses, the clinical features of which, to
some extent, overlap, is critical for the effective management
of this devastating infection. Unfortunately, the non-speciﬁc
clinical presentation of mucormycosis, combined with the
intrinsic difﬁculty in diagnosis, impedes the rapid deﬁnitive
diagnosis and treatment of the infection.
Deﬁnitive diagnosis requires histopathological proof of
mycelia in tissue samples, with or without positive culture.
However, 30% of histopathology-proven mucormycosis sam-
ples are culture-negative and there is a 20% discordance
between morphology-based and sequencing-based identiﬁca-
tion [5]. In addition, laboratory contaminants can accidentally
contribute to false positive results [23], and the isolation of
fungi causing mucormycosis from sputum or bronchoalveolar
lavage specimens is not synonymous with invasive infection,
even in cancer patients [6]. Recently, real-time quantitative
polymerase chain reaction (qPCR) assays in a rabbit model,
performed by targeting the 28S rRNA gene showed promise
for the diagnosis of some Mucorales species [24]. However,
how much promise this technique holds as a clinical applica-
tion remains unknown. Another potentially useful diagnostic
algorithm is the combination of a computed tomography
(CT)-guided percutaneous biopsy and non-culture based
diagnostics (Galactomannan (GM), PCR) in patients with
invasive pulmonary infections where mucormycosis is
included in the differential diagnosis [25].
If the results of Aspergillus PCR and/or GM enzyme
immunoassay (EIA) are negative, the physician should have
an even higher level of suspicion of mucormycosis and
request a PCR test speciﬁc for mucormycosis and should
change therapy to drugs with activity against it [25].
Regarding the clinical presentation of mucormycosis in
patients with haematological malignancies, a signiﬁcant over-
lap exists with invasive pulmonary aspergillosis (IPA). The
presence of sinusitis, VRC pre-exposure and multiple nod-
ules (>10) with micronodules (<1 cm) in chest CT favour
the diagnosis of mucormycosis [26].
Increased expression of
efflux pumps sexreting
virulence factors (e.g., proteases)
Enhanced angioinvasion with
hemorrhagic necrosis
Fe2+
Increased adherence to endothelial surfaces
or extracellular matrix
Increased secretion of
iron scavenging siderophores
FIG. 1. Possible epigenetic mechanisms of
increased virulence in Rhizopus oryzae follow-
ing voriconazole exposure.
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Any delay in differentiating between pulmonary mucormy-
cosis and IPA can have a devastating consequence for patient
survival [27]. For example, in a study of patients with haema-
tological malignancies, Chamilos et al. [27] showed that
delaying amphotericin B (AmB)-based treatment for >6 days
after the onset of symptoms of mucormycosis can result in a
two-fold increase in mortality rate, compared with early
treatment, and a <20% survival rate at 12 weeks after diag-
nosis. This delay, along with severity of the active malignancy
and monocytopenia, was independently associated with a
poor outcome.
Treatment
Voriconazole-associated mucormycosis appears to have a
poor outcome, perhaps reﬂecting the advanced immuno-
suppressive state of infected patients along with the aggres-
siveness of the infection. In a multicentre retrospective study,
Triﬁlio et al. [28] described a 73% mortality rate in patients
with this type of infection, but found no particular association
between the causative Mucorales and the type of infection.
There is no systematic clinical experience with the treat-
ment of VRC-associated mucormycosis, a disease in which
therapeutic options are limited. AmB has been the standard
therapy against mucormycosis [29], but over the last decade,
because of the nephrotoxicity problems associated with the
high doses required to treat this refractory infection, lipid
formulations of AmB have become the preferred therapy
[30, 31].
Well-tolerated, orally administered agents with activity
against Mucorales are clearly needed for the long-term man-
agement of mucormycosis. Posaconazole is an extended-
spectrum, orally administered triazole with proven activity
in vitro against Mucorales, both in an immunosuppressed
mouse model of mucormycosis and in humans as salvage
therapy against mucormycosis [32,33]. Whether prior expo-
sure of Mucorales to VRC ‘devitalizes’ the subsequent activity
of posaconazole remains an important, as yet unresolved,
question as triazole cross-resistance has been described in
Aspergillus species. However, in view of its activity against IA
and mucormycosis, posaconazole may represent a preferable
treatment option because it may be able to prevent both of
these IFIs.
Conclusions
Voriconazole prophylaxis has been associated in retrospec-
tive case series and prospective epidemiological surveillance
programmes with increased numbers of reports of muco-
rmycosis. Although emerging preclinical data suggest that
VRC exposure can modulate the virulence of some Muco-
rales, the clinical implications of these ﬁndings remain
unknown. Many questions concerning the host and immuno-
suppression-speciﬁc risk factors that may be driving an
increase in the incidence of mucormycosis remain answered,
as do questions about the optimal approach towards diag-
nosing and treating the increasingly complex cases of this
devastating infection (Table 2). Future experimental and clini-
cal studies are required to clarify causality and to establish
better diagnostic, therapeutic and prophylactic algorithms for
VRC-associated mucormycosis.
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